Position in GUTS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$103,395
-$60,507 QoQ
Shares Held
130,221
-63.6% QoQ
Ownership
0.082%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
#32
of 76 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in GUTS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Shay Capital LLC holds $28,920,887 across 40 Biotechnology names. GUTS ranks #33 (0.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | DFTX |
Definium Therapeutics, Inc.
|
80,000 | $3,763,200 | |
| 2 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
44,000 | $3,586,440 | |
| 3 | RVMD |
Revolution Medicines, Inc.
|
12,500 | $2,341,000 | |
| 4 | MANE |
Veradermics, Inc
|
19,000 | $2,335,860 | |
| 5 | BCAX |
Bicara Therapeutics Inc.
|
68,000 | $2,018,920 | |
| 6 | QURE |
uniQure N.V.
|
37,419 | $1,723,519 | |
| 7 | AVLN |
Avalyn Pharma Inc.
|
40,000 | $1,316,800 | |
| 8 | PGEN |
Precigen, Inc.
|
190,000 | $1,083,000 |
All Filings in GUTS
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $103,395 | 130,221 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $163,902 | 357,865 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $300,449 | 136,568 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $453,471 | 285,202 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||